Somatostatin, Alzheimer's disease and cognition: An old story coming of age?

Progress in Neurobiology

Volumn 89, Issue 2, 2009, Pages 153-161

  Epelbaum, Jacques ^a   Guillou, Jean Louis ^b   Gastambide, François ^b   Hoyer, Daniel ^c   Duron, Emmanuelle ^a   Viollet, Cécile ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

amyloid; Cortistatin; Cysteamine; Hippocampus; Somatostatin; sst2; sst4; Striatum; Tau

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; CORTISTATIN; CORTISTATIN RECEPTOR; DONEPEZIL; MERCAPTAMINE; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; NEUROPEPTIDE RECEPTOR; OCTREOTIDE; SOMATOSTATIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; BRAIN FUNCTION; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; DRUG POTENTIATION; EMOTION; HIPPOCAMPUS; HUMAN; KNOCKOUT MOUSE; MEMORY DISORDER; NEOCORTEX; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM; COGNITION; HUMANS; NEUROPEPTIDES; SOMATOSTATIN;

EID: 70249110364     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.07.002     Document Type: Review

References (142)

1. Ascoli G.A., Alonso-Nanclares L., Anderson S.A., Barrionuevo G., Benavides-Piccione R., Burkhalter A., Buzsáki G., Cauli B., Defelipe J., Fairén A., Feldmeyer D., Fishell G., Fregnac Y., Freund T.F., Gardner D., Gardner E.P., Goldberg J.H., Helmstaedter M., Hestrin S., Karube F., Kisvárday Z.F., Lambolez B., Lewis D.A., Marin O., Markram H., Muñoz A., Packer A., Petersen C.C., Rockland K.S., Rossier J., Rudy B., Somogyi P., Staiger J.F., Tamas G., Thomson A.M., Toledo-Rodriguez M., Wang Y., West D.C., and Yuste R. Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex. Nat. Rev. Neurosci. 9 7 (2008) 557-568
2. Allen J.P., Hathway G.J., Clarke N.J., Jowett M.I., Topps S., Kendrick K.M., Humphrey P.P., Wilkinson L.S., and Emson P.C. Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Eur. J. Neurosci. 17 9 (2003) 1881-1895
3. Arancibia S., Payet O., Givalois L., and Tapia-Arancibia L. Acute stress and dexamethasone rapidly increase hippocampal somatostatin synthesis and release from the dentate gyrus hilus. Hippocampus 11 4 (2001) 469-477
4. Arendash G.W., Millard W.J., Dawson Jr. R., Dunn A.J., and Meyer E.M. Different long-term effects of bilateral and unilateral nucleus basalis lesions on rat cerebral cortical neurotransmitter content. Neurochem. Res. 14 11 (1989) 1113-1118
5. Bakhit C., and Swerdlow N. Behavioral changes following central injection of cysteamine in rats. Brain Res. 365 1 (1986) 159-163
6. Bao W., and Wu J.Y. Propagating wave and irregular dynamics: spatiotemporal patterns of cholinergic theta oscillations in neocortex in vitro. J. Neurophysiol. 90 (2003) 333-341
7. Baraban S.C., and Tallent M.K. Interneuron diversity series: interneuronal neuropeptides-endogenous regulators of neuronal excitability. Trends Neurosci. 27 3 (2004) 135-142
8. 2+ signaling in mouse dentate gyrus. J. Neurophysiol. 88 6 (2002) 3078-3086
9. Beal M.F., Mazurek M.F., Tran V.T., Chattha G., Bird E.D., and Martin J.B. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 229 4710 (1985) 289-291
10. Bergström L., Garlind A., Nilsson L., Alafuzoff I., Fowler C.J., Winblad B., and Cowburn R.F. Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain. J. Neurol. Sci. 105 2 (1991) 225-233
11. Bissette G., and Myers B. Somatostatin in Alzheimer's disease and depression. Life Sci 51 (1992) 1389-1410
12. Blanchard J., Martel G., Guillou J.L., Noguès X., and Micheau J. Impairment of spatial memory consolidation in APP(751SL) mice results in cue-guided response. Neurobiol. Aging 29 7 (2008) 1011-1021
13. Bollok I., Vecsei L., and Telegdy G. The effects of interaction between propranolol and somatostatin on the active avoidance behavior, open-field activity and electroconvulsive shock-induced amnesia of rats. Neuropeptides 3 4 (1983) 263-270
14. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., and Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 68 (1973) 77-79
15. Broglio F., Grottoli S., Arvat E., and Ghigo E. Endocrine actions of cortistatin: In vivo studies. Mol. Cell Endocrinol. 286 1-2 (2008) 123-127
16. Bruns C., Raulf F., Hoyer D., Schloos J., Lübbert H., and Weckbecker G. Binding properties of somatostatin receptor subtypes. Metabolism 45 8 Suppl 1 (1996) 17-20
17. Cammalleri M., Cervia D., Dal Monte M., Martini D., Langenegger D., Fehlmann D., Feuerbach D., Pavan B., Hoyer D., and Bagnoli P. Compensatory changes in the hippocampus of somatostatin knockout mice: upregulation of somatostatin receptor 2 and its function in the control of bursting activity and synaptic transmission. Eur. J. Neurosci. 23 9 (2006) 2404-2422
18. Canolty R.T., Edwards E., Dalal S.S., Soltani M., Nagarajan S.S., Kirsch H.E., Berger M.S., Barbaro N.M., and Knight R.T. High gamma power is phase-locked to theta oscillations in human neocortex. Science 313 (2006) 1626-1628
19. Craft S., Asthana S., Newcomer J.W., Wilkinson C.W., Matos I.T., Baker L.D., Cherrier M., Lofgreen C., Latendresse S., Petrova A., Plymate S., Raskind M., Grimwood K., and Veith R.C. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 56 12 (1999) 1135-1140
20. Csaba Z., and Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 35 1 (2001) 1-23
21. Davies P., Katzman R., and Terry R.D. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 288 5788 (1980) 279-280
22. Deghenghi R., Papotti M., Ghigo E., and Muccioli G. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J. Endocrinol. Invest. 24 1 (2001) RC1-RC3
23. de Lecea L. Cortistatin-functions in the central nervous system. Mol. Cell Endocrinol. 286 1-2 (2008) 88-95
24. de Lecea L., Criado J.R., Prospero-Garcia O., Gautvik K.M., Schweitzer P., Danielson P.E., Dunlop C.L., Siggins G.R., Henriksen S.J., and Sutcliffe J.G. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature 381 6579 (1996) 242-245
25. de Noble V.J., Hepler D.J., and Barto R.A. Cysteamine-induced depletion of somatostatin produces differential cognitive deficits in rats. Brain Res. 482 1 (1989) 42-48
26. Diamond D.M., Campbell A.M., Park C.R., Halonen J., and Zoladz P.R. The temporal dynamics model of emotional memory processing: a synthesis on the neurobiological basis of stress-induced amnesia, flashbulb and traumatic memories, and the Yerkes-Dodson law. Neural Plast (2007) 60803
27. Dournaud P., Delaere P., Hauw J.J., and Epelbaum J. Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol. Aging 16 5 (1995) 817-823
28. Dutar P., Vaillend C., Viollet C., Billard J.M., Potier B., Carlo A.S., Ungerer A., and Epelbaum J. Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knock-out mice. Neuroscience 112 2 (2002) 455-466
29. Eichenbaum H. The Hippocampal System and Declarative Memory in Humans and Animals: Experimental Analysis and Historical Origins. A Bradford Book (1994), The MIT Press, Cambridge, MA pp. 147-201
30. Engin E., Stellbrink J., Treit D., and Dickson C.T. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 157 3 (2008) 666-676
31. Epelbaum J. Somatostatin in the central nervous system: physiology and pathological modifications. Prog. Neurobiol. 27 (1986) 63-100
32. Epelbaum J., Lamour Y., Enjalbert A., Hamon M., Dutar P., and Kordon C. Modifications in the cortical regional distribution of choline acetyltransferase, somatostatin and somatostatin binding sites in the normal rat and following lesion of the nucleus basalis. Brain Res. 371 2 (1986) 376-379
33. Fanselow E.E., Richardson K.A., and Connors B.W. Selective, state-dependent activation of somatostatin-expressing inhibitory interneurons in mouse neocortex. J. Neurophysiol. 100 5 (2008) 2640-2652
34. Fitzgerald L.W., and Dokla C.P. Morris water task impairment and hypoactivity following cysteamine-induced reductions of somatostatin-like immunoreactivity. Brain Res. 505 2 (1989) 246-250
35. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front. Biosci. 13 (2008) 822-840
36. Gabriel S.M., Davidson M., Haroutunian V., Powchik P., Bierer L.M., Purohit D.P., Perl D.P., and Davis K.L. Neuropeptide deficits in schizophrenia vs Alzheimer's disease cerebral cortex. Biol. Psychiatry 39 (1996) 82-91
37. Gastambide, F., Lepousez, G., Viollet, C., Loudes, C., Epelbaum, J., Guillou, J.L., 2009a. Cooperation between hippocampal somatostatin receptor subtypes 4 and 2: functional relevance in interactive memory systems. Hippocampus, in press (DOI:10.1002/hipo.20680).
38. Gastambide, F., Viollet, C., Lepousez, G., Epelbaum, J., Guillou, J.L., 2009b. Hippocampal SSTR4 somatostatin receptors control the selection of memory strategies. Psychopharmacology (Berlin) 202 (1-3), 153-163.
39. Gaykema R.P., Compaan J.C., Nyakas C., Horvath E., and Luiten P.G. Long-term effects of cholinergic basal forebrain lesions on neuropeptide Y and somatostatin immunoreactivity in rat neocortex. Brain Res. 489 2 (1989) 392-396
40. Gonzalez-Rey E., and Delgado M. Emergence of cortistatin as a new immunomodulatory factor with therapeutic potential in immune disorders. Molecular and Cellular Endocrinology 286 (2008) 135-140
41. Gray J.A. The Neuropsychology of Anxiety (1982), Oxford University Press: Oxford
42. Gray J.A., and McNaughton N. The Neuropsychology of Anxiety: An enquiry into the function of the septo-hippocampal system (2003), Oxford University Press: Oxford
43. Grouselle D., Winsky-Sommerer R., David J.P., Delacourte A., Dournaud P., and Epelbaum J. Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci. Lett. 255 1 (1998) 21-24
44. Guillou J.L., Micheau J., and Jaffard R. Effects of intrahippocampal injections of somatostatin and cysteamine on spatial discrimination learning in mice. Psychobiology 21 4 (1993) 265-271
45. Guillou J.L., Micheau J., and Jaffard R. The opposite effects of cysteamine on the acquisition of two different tasks in mice are associated with bidirectional testing-induced changes in hippocampal adenylyl cyclase activity. Behav. Neurosci. 112 4 (1998) 900-908
46. Guillou J.L., Micheau J., and Jaffard R. Intrahippocampal injections of cysteamine improve the retention of a bar-pressing task in mice. Behav. Brain Res. 103 1 (1999) 113-117
47. Halabisky B., Shen F., Huguenard J.R., and Prince D.A. Electrophysiological classification of somatostatin-positive interneurons in mouse sensorimotor cortex. J. Neurophysiol. 96 2 (2006) 834-845
48. Hanger D., Anderton B., and Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends in Molecular Medicine 15 (2009) 112-119
49. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52 October (1) (2006) 3-13
50. Haroutunian V., Mantin R., Campbell G.A., Tsuboyama G.K., and Davis K.L. Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Brain Res. 403 2 (1987) 234-242
51. Haroutunian V., Kanof P.D., and Davis K.L. Interactions of forebrain cholinergic and somatostatinergic systems in the rat. Brain Res 496 (1989) 98-104
52. Hashimoto T., Arion D., Unger T., Maldonado-Aviles J.G., Morris H.M., Volk D.W., Mirnics K., and Lewis D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 13 2 (2008) 147-161
53. Horgan J., Miguel-Hidalgo J.J., Thrasher M., and Bissette G. Longitudinal brain corticotropin releasing factor and somatostatin in a transgenic mouse (TG2576) model of Alzheimer's disease. J. Alzheimers Dis. 12 2 (2007) 115-127
54. Hoyer D., Bell G.I., Berelowitz M., Epelbaum J., Feniuk W., Humphrey P.P., O'Carroll A.M., Patel Y.C., Schonbrunn A., Taylor J.E., and Reisine T. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 16 3 (1995) 86-88
55. Iwata N., Higuchi M., and Saido T.C. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 108 2 (2005) 129-148
56. Inoue T., Wang F., Moriguchi A., Shirakawa K., Matsuoka N., and Goto T. FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 892 1 (2001) 111-117
57. Jaehde U., Masereeuw R., De Boer A.G., Fricker G., Nagelkerke J.F., Vonderscher J., and Breimer D.D. Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharm. Res. 11 3 (1994) 442-448
58. Justino L., Welner S.A., Tannenbaum G.S., and Schipper H.M. Long-term effects of cysteamine on cognitive and locomotor behavior in rats: relationship to hippocampal glial pathology and somatostatin levels. Brain Res. 761 1 (1997) 127-134
59. Kamohara M., Matsuo A., Takasaki J., Kohda M., Matsumoto M., Matsumoto S., Soga T., Hiyama H., Kobori M., and Katou M. Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. Biochem. Biophys. Res. Commun. 330 4 (2005) 1146-1152
60. Kawaguchi Y., and Kubota Y. GABAergic cell subtypes and their synaptic connections in rat frontal cortex. Cereb. Cortex 7 (1997) 476-486
61. Kim J.J., Lee H.J., Han J.S., and Packard M.G. Amygdala is critical for stress-induced modulation of hippocampal long-term potentiation and learning. J. Neurosci. 21 14 (2001) 5222-5228
62. Kluge C., Stoppel C., Szinyei C., Stork O., and Pape H.C. Role of the somatostatin system in contextual fear memory and hippocampal synaptic plasticity. Learn. Mem. 15 4 (2008) 252-260
63. Kocharyan A., Fernandes P., Tong X.K., Vaucher E., and Hamel E. Specific subtypes of cortical GABA interneurons contribute to the neurovascular coupling response to basal forebrain stimulation. J. Cereb. Blood Flow Metab. 28 2 (2008) 221-231
64. Kramer D., Caruso A., Nicoletti F., and Genazzani A.A. Somatostatin and the somatostatin receptor 2 are reciprocally controlled by calcineurin during cerebellar granule cell maturation. J. Neurochem. 94 5 (2005) 1374-1383
65. Krantic S., Robitaille Y., and Quirion R. Deficits in the somatostatin SS1 receptor sub-type in frontal and temporal cortices in Alzheimer's disease. Brain Res. 573 2 (1992) 299-304
66. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 134 2 (2005) 525-538
67. Lamour Y., and Epelbaum J. Interactions between cholinergic and peptidergic systems in the cerebral cortex and hippocampus. Prog. Neurobiol. 31 2 (1988) 109-148
68. Lamirault L., Guillou J.L., Micheau J., and Jaffard R. Intrahippocampal injections of somatostatin dissociate acquisition from the flexible use of place responses. Eur. J. Neurosci. 14 3 (2001) 567-570
69. Lee A.S., Duman R.S., and Pittenger C. A double dissociation revealing bidirectional competition between striatum and hippocampus during learning. Proc. Natl. Acad. Sci. U.S.A. 105 44 (2008) 17163-17168
70. Lewis D.A., and González-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33 1 (2008) 141-165
71. Lewis D.A., Hashimoto T., and Morris H.M. Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotoxicol. Res. 14 2-3 (2008) 237-248
72. Ma Y., Hu H., Berrebi A.S., Mathers P.H., and Agmon A. Distinct subtypes of somatostatin-containing neocortical interneurons revealed in transgenic mice. J. Neurosci. 26 (2006) 5069-5082
73. Markram H., Toledo-Rodriguez M., Wang Y., Gupta A., Silberberg G., and Wu C. Interneurons of the neocortical inhibitory system. Nat. Rev. Neurosci. 5 10 (2004) 793-807
74. Martel G., Blanchard J., Mons N., Gastambide F., Micheau J., and Guillou J.L. Dynamic interplays between memory systems depend on practice: the hippocampus is not always the first to provide solution. Neuroscience 150 (2007) 743-753
75. Matsuoka N., Kaneko S., and Satoh M. Somatostatin augments long-term potentiation of the mossy fiber-CA3 system in guinea-pig hippocampal slices. Brain Res. 553 2 (1991) 188-194
76. Matsuoka N., Kaneko S., and Satoh M. A facilitatory role of endogenous somatostatin in long-term potentiation of the mossy fiber-CA3 system in guinea-pig hippocampus. Neurosci. Lett. 129 2 (1991) 177-180
77. Matsuoka N., Yamazaki M., and Yamaguchi I. Changes in brain somatostatin in memory-deficient rats: comparison with cholinergic markers. Neuroscience 66 3 (1995) 617-626
78. Matsuoka N., and Satoh M. FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices. Brain Res. 794 2 (1998) 248-254
79. Matsuoka N., and Aigner T.G. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine. J. Pharmacol. Exp. Ther. 280 3 (1997) 1201-1209
80. Melchitzky D.S., and Lewis D.A. Dendritic-targeting GABA neurons in monkey prefrontal cortex: comparison of somatostatin- and calretinin-immunoreactive axon terminals. Synapse 62 6 (2008) 456-465
81. Méndez-Díaz M., Irwin L., Gómez-Chavarín M., Jiménez-Anguiano A., Cabeza R., Murillo-Rodríguez E., and Prospéro-García O. Cortistatin modulates memory evocation in rats. Eur. J. Pharmacol. 507 1-3 (2005) 21-28
82. Moneta D., Richichi C., Aliprandi M., Dournaud P., Dutar P., Billard J.M., Carlo A.S., Viollet C., Hannon J.P., Fehlmann D., Nunn C., Hoyer D., Epelbaum J., and Vezzani A. Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur. J. Neurosci. 16 5 (2002) 843-849
83. Morris H.M., Hashimoto T., and Lewis D.A. Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb. Cortex 18 7 (2008) 1575-1587
84. Moyse E., Szigethy E., Danger J.M., Vaudry H., Wenk G.L., Beaudet A., and Epelbaum J. Short- and long-term effects of nucleus basalis magnocellularis lesions on cortical levels of somatostatin and its receptors in the rat. Brain Res. 607 1-2 (1993) 154-160
85. Nag S., and Tang F. Cholinergic lesions of the rat brain by ibotenic acid and 192 IgG-saporin: effects on somatostatin, substance P and neuropeptide Y levels in the cerebral cortex and the hippocampus. Neurosci. Lett. 252 2 (1998) 83-86
86. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol. 3 9 (2004) 519-527
87. Olias G., Viollet C., Kusserow H., Epelbaum J., and Meyerhof W. Regulation and function of somatostatin receptors. J. Neurochem. 89 5 (2004) 1057-1091
88. Oliva Jr. A.A., Jiang M., Lam T., Smith K.L., and Swann J.W. Novel hippocampal interneuronal subtypes identified using transgenic mice that express green fluorescent protein in GABAergic interneurons. J. Neurosci. 20 (2000) 3354-3368
89. Pardon M.C., and Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders?. Neurosci. Biobehav. Rev. 32 6 (2008) 1103-1120
90. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20 3 (1999) 157-198
91. Patel Y.C., and Srikant C.B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 135 6 (1994) 2814-2817
92. Pessoa L. On the relationship between emotion and cognition. Nat. Rev. Neurosci. 9 2 (2008) 148-158
93. Poldrack R.A., and Packard M.G. Competition among multiple memory systems: converging evidence from animal and human brain studies. Neuropsychologia 41 3 (2003) 245-251
94. Potier B., Jouvenceau A., Epelbaum J., and Dutar P. Age-related alterations of GABAergic input to CA1 pyramidal neurons and its control by nicotinic acetylcholine receptors in rat hippocampus. Neuroscience 142 1 (2006) 187-201
95. Pradayrol L., Chayvialle J.A., Carlquist M., and Mutt V. Isolation of a porcine intestinal peptide with C-terminal somatostatin. Biochem. Biophys. Res. Commun. 85 2 (1978) 701-708
96. Raghavachari S., Lisman J.E., Tully M., Madsen J.R., Bromfield E.B., and Kahana M.J. Theta oscillations in human cortex during a working-memory task: evidence for local generators. J. Neurophysiol. 95 (2006) 1630-1638
97. Ramos B., Baglietto-Vargas D., del Rio J.C., Moreno-Gonzalez I., Santa-Maria C., Jimenez S., Caballero C., Lopez-Tellez J.F., Khan Z.U., Ruano D., Gutierrez A., and Vitorica J. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol. Aging 27 11 (2006) 1658-1672
98. Reichlin S. Somatostatin. N. Engl. J. Med. 309 24 (1983) 1495-1501
99. Reichlin S. Somatostatin (second of two parts). N. Engl. J. Med. 309 25 (1983) 1556-1563
100. Reyes A., Lujar R., Rozov B.N., Somogyi P., and Sakman B. Target-cell-specific facilitation and depression in neocortical circuits. Nat. Neurosci. 1 (1998) 279-285
101. Robas N., Mead E., and Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. 278 45 (2003) 44400-44404
102. Rohrer S.P., Birzin E.T., Mosley R.T., Berk S.C., Hutchins S.M., Shen D.M., Xiong Y., Hayes E.C., Parmar R.M., Foor F., Mitra S.W., Degrado S.J., Shu M., Klopp J.M., Cai S.J., Blake A., Chan W.W., Pasternak A., Yang L., Patchett A.A., Smith R.G., Chapman K.T., and Schaeffer J.M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282 5389 (1998) 737-740
103. Rostampour M., Fathollahi Y., Semnanian S., Hajizadeh S., Mirnajafizadeh J., and Shafizadeh M. The ability of hippocampal CA1 area for induction of long-term potentiation is persistently reduced by prior treatment with cysteamine: an in vitro study. Neuropeptides 36 (2002) 263-270
104. Rubio A., Avila J., and de Lecea L. Cortistatin as a therapeutic target in inflammation. Expert Opin. Ther. Targets 11 1 (2007) 1-9
105. Rubio A., Pérez M., de Lecea L., and Avila J. Effect of cortistatin on tau phosphorylation at Ser262 site. J. Neurosci. Res. 86 11 (2008) 2462-2475
106. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., Suemoto T., Higuchi M., and Saido T.C. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 11 4 (2005) 434-439
107. Sánchez-Alavez M., Gómez-Chavarín M., Navarro L., Jiménez-Anguiano A., Murillo-Rodríguez E., Prado-Alcalá R.A., Drucker-Colin R., and Prospéro-García O. Cortistatin modulates memory processes in rats. Brain Res. 858 1 (2000) 78-83
108. Savonenko A., Xu G.M., Melnikova T., Morton J.L., Gonzales V., Wong M.P., Price D.L., Tang F., Markowska A.L., and Borchelt D.R. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol. Dis. 18 3 (2005) 602-617
109. Schettini G., Florio T., Magri G., Grimaldi M., Meucci O., Landolfi E., and Marino A. Somatostatin and SMS 201-995 reverse the impairment of cognitive functions induced by cysteamine depletion of brain somatostatin. Eur. J. Pharmacol. 151 3 (1988) 399-407
110. Schwabe L., Oitzl M.S., Philippsen C., Richter S., Bohringer A., Wippich W., and Schachinger H. Stress modulates the use of spatial versus stimulus-response learning strategies in humans. Learn. Mem. 14 1 (2007) 109-116
111. Schwabe L., Dalm S., Schächinger H., and Oitzl M.S. Chronic stress modulates the use of spatial and stimulus-response learning strategies in mice and man. Neurobiol. Learn. Mem. 90 3 (2008) 495-503
112. Siehler S., and Hoyer D. Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity. Naunyn Schmiedebergs Arch. Pharmacol. 360 5 (1999) 510-521
113. Siehler S., and Hoyer D. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity. Naunyn Schmiedebergs Arch. Pharmacol. 360 5 (1999) 522-532
114. Siehler S., Nunn C., Hannon J., Feuerbach D., and Hoyer D. Pharmacological profile of somatostatin and cortistatin receptors. Mol. Cell. Endocrinol. 286 1-2 (2008) 26-34
115. Silva L.R., Amitai Y., and Connors B.W. Intrinsic oscillations of neocortex generated by layer 5 pyramidal neurons. Science 251 (1991) 432-435
116. Squire L.R. Memory systems of the brain: a brief history and current perspective. Neurobiol. Learn. Mem. 82 3 (2004) 171-177
117. Stanić D., Malmgren H., He H., Scott L., Aperia A., and Hökfelt T. Developmental changes in frequency of the ciliary somatostatin receptor 3 protein. Brain Res. 1249 (2009) 101-112
118. Stroh T., Kreienkamp H.J., and Beaudet A. Immunohistochemical distribution of the somatostatin receptor subtype 5 in the adult rat brain: predominant expression in the basal forebrain. J. Comp. Neurol. 412 1 (1999) 69-82
119. Szabo S., and Reichlin S. Somatostatin in rat tissues is depleted by cysteamine administration. Endocrinology 109 6 (1981) 2255-2257
120. Tallent M.K. Somatostatin in the dentate gyrus. Prog. Brain Res. 163 (2007) 265-284
121. Tallent M.K., Fabre V., Qiu C., Calbet M., Lamp T., Baratta M.V., Suzuki C., Levy C.L., Siggins G.R., Henriksen S.J., Criado J.R., Roberts A., and de Lecea L. Cortistatin overexpression in transgenic mice produces deficits in synaptic plasticity and learning. Mol. Cell. Neurosci. 30 3 (2005) 465-475
122. Tamminga C.A., Foster N.L., Fedio P., Bird E.D., and Chase T.N. Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 37 1 (1987) 161-165
123. Terry R.D., and Katzman R. Senile dementia of the Alzheimer type. Ann. Neurol. 14 5 (1983) 497-506
124. 1 receptor: an autoreceptor for somatostatin in brain and retina?. Pharmacol. Ther. 110 3 (2006) 455-464
125. Tokita K., Yamazaki S., Yamazaki M., Matsuoka N., and Mutoh S. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol. Biochem. Behav. 73 3 (2002) 511-519
126. Tostivint H., Joly L., Lihrmann I., Parmentier C., Lebon A., Morisson M., Calas A., Ekker M., and Vaudry H. Comparative genomics provides evidence for close evolutionary relationships between the urotensin II and somatostatin gene families. Proc. Natl. Acad. Sci. U.S.A. 103 7 (2006) 2237-2242
127. Vecsei L., Bollok I., and Telegdy G. Intracerebroventricular somatostatin attenuates electroconvulsive shock-induced amnesia in rats. Peptides 4 3 (1983) 293-295
128. Vecsei L., Kiraly C., Bollok I., Nagy A., Varga J., Penke B., and Telegdy G. Comparative studies with somatostatin and cysteamine in different behavioral tests on rats. Pharmacol. Biochem. Behav. 21 6 (1984) 833-837
129. Vecsei L., and Widerlov E. Effects of intracerebroventricularly administered somatostatin on passive avoidance, shuttle-box behaviour and open-field activity in rats. Neuropeptides 12 4 (1988) 237-242
130. Vécsei L., Alling C., and Widerlöv E. Comparative studies of intracerebroventricularly administered cysteamine and pantethine in different behavioral tests and on brain catecholamines in rats. Arch. Int. Pharmacodyn. Ther. 305 (1990) 140-151
131. Vepsäläinen S., Helisalmi S., Koivisto A.M., Tapaninen T., Hiltunen M., and Soininen H. Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients. J. Neurol. 254 11 (2007) 1504-1508
132. Viana F., and Hille B. Modulation of high voltage-activated calcium channels by somatostatin in acutely isolated rat amygdaloid neurons. J. Neurosci. 16 19 (1996) 6000-6011
133. 2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur. J. Neurosci. 12 10 (2000) 3761-3770
134. Viollet C., Lepousez G., Loudes C., Videau C., Simon A., and Epelbaum J. Somatostatinergic systems in brain: Networks and functions. Molecular and Cellular Endocrinology 286 (2008) 75-87
135. Wang F., Matsuoka N., Mutoh S., and Kaneko S. Modulation of Ca2+ channel currents by a novel antidementia drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960) in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 308 1 (2004) 120-126
136. Wang X.J., Tegner J., Constantinidis C., and Goldman-Rakic P.S. Division of labor among distinct subtypes of inhibitory neurons in a cortical microcircuit of working memory. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1368-1373
137. Wang J.Z., Grundke-Iqbal I., and Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25 1 (2007) 59-68
138. White N.M., and McDonald R.J. Multiple parallel memory systems in the brain of the rat. Neurobiol. Learn. Mem. 77 2 (2002) 125-184
139. 5 receptor. Br. J. Pharmacol. 118 3 (1996) 445-447
140. Yamazaki M., Matsuoka N., Maeda N., Ohkubo Y., and Yamaguchi I. FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. J. Pharmacol. Exp. Ther. 279 3 (1996) 1157-1173
141. Ziegler-Graham K., Brookmeyer R., Johnson E., and Arrighi H.M. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 4 5 (2008) 316-323
142. Zigman J.M., Jones J.E., Lee C.E., Saper C.B., and Elmquist J.K. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J. Comp. Neurol. 494 3 (2006) 528-548